

# Kim A Caldwell

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/7937826/kim-a-caldwell-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

99  
papers

7,699  
citations

43  
h-index

87  
g-index

111  
ext. papers

8,647  
ext. citations

8  
avg, IF

5.43  
L-index

| #  | Paper   | IF   | Citations |
|----|---|------|-----------|
| 99 | Amelioration of Alzheimer's disease pathology by mitophagy inducers identified via machine learning and a cross-species workflow.. <i>Nature Biomedical Engineering</i> , <b>2022</b> , 6, 76-93  | 19   | 14        |
| 98 | A conformational switch driven by phosphorylation regulates the activity of the evolutionarily conserved SNARE Ykt6. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2021</b> , 118,                    | 11.5 | 5         |
| 97 | Neurodegenerative VPS41 variants inhibit HOPS function and mTORC1-dependent TFEB/TFE3 regulation. <i>EMBO Molecular Medicine</i> , <b>2021</b> , 13, e13258   | 12   | 3         |
| 96 | Conserved nicotine-activated neuroprotective pathways involve mitochondrial stress. <i>iScience</i> , <b>2021</b> , 24, 102140  | 6.1  | 4         |
| 95 | Bcl-xL Is Required by Primary Hippocampal Neurons during Development to Support Local Energy Metabolism at Neurites. <i>Biology</i> , <b>2021</b> , 10,   | 4.9  | 1         |
| 94 | Therapeutic genetic variation revealed in diverse Hsp104 homologs. <i>ELife</i> , <b>2020</b> , 9,  | 8.9  | 6         |
| 93 | Modeling neurodegeneration in. <i>DMM Disease Models and Mechanisms</i> , <b>2020</b> , 13,   | 4.1  | 28        |
| 92 | ApoE-associated modulation of neuroprotection from A $\beta$ -mediated neurodegeneration in transgenic. <i>DMM Disease Models and Mechanisms</i> , <b>2019</b> , 12,  | 4.1  | 14        |
| 91 | Cyclized NDGA modifies dynamic $\beta$ -synuclein monomers preventing aggregation and toxicity. <i>Scientific Reports</i> , <b>2019</b> , 9, 2937   | 4.9  | 20        |
| 90 | Found in Translation: The Utility of Alpha-Synuclein Models of Parkinson's Disease. <i>Brain Sciences</i> , <b>2019</b> , 9,  | 3.4  | 21        |
| 89 | Genetic Defects in Mitochondrial Dynamics in Impact Ultraviolet C Radiation- and 6-hydroxydopamine-Induced Neurodegeneration. <i>International Journal of Molecular Sciences</i> , <b>2019</b> , 20,  | 6.3  | 7         |
| 88 | Vacuolar protein sorting protein 41 (VPS41) at an intersection of endosomal traffic in neurodegenerative disease. <i>Neural Regeneration Research</i> , <b>2019</b> , 14, 1210-1212   | 4.5  | 1         |
| 87 | Alpha-synuclein inhibits Snx3-retromer-mediated retrograde recycling of iron transporters in <i>S. cerevisiae</i> and <i>C. elegans</i> models of Parkinson's disease. <i>Human Molecular Genetics</i> , <b>2018</b> , 27, 1514-1532 <sup>5,6</sup> | 5.6  | 20        |
| 86 | The Small GTPase RAC1/CED-10 Is Essential in Maintaining Dopaminergic Neuron Function and Survival Against $\beta$ -Synuclein-Induced Toxicity. <i>Molecular Neurobiology</i> , <b>2018</b> , 55, 7533-7552   | 6.2  | 25        |
| 85 | Gene-by-environment interactions that disrupt mitochondrial homeostasis cause neurodegeneration in <i>C. elegans</i> Parkinson's models. <i>Cell Death and Disease</i> , <b>2018</b> , 9, 555   | 9.8  | 16        |
| 84 | Distinct functional roles of Vps41-mediated neuroprotection in Alzheimer's and Parkinson's disease models of neurodegeneration. <i>Human Molecular Genetics</i> , <b>2018</b> , 27, 4176-4193   | 5.6  | 13        |
| 83 | No Country for Old Worms: A Systematic Review of the Application of to Investigate a Bacterial Source of Environmental Neurotoxicity in Parkinson's Disease. <i>Metabolites</i> , <b>2018</b> , 8,  | 5.6  | 5         |

|    |  |      |     |
|----|--|------|-----|
| 82 | C. elegans as a model system to accelerate discovery for Parkinson disease. <i>Current Opinion in Genetics and Development</i> , <b>2017</b> , 44, 102-109   | 4.9  | 38  |
| 81 | Dihydropyrimidine-Thiones and Cloiquinol Synergize To Target $\beta$ Amyloid Cellular Pathologies through a Metal-Dependent Mechanism. <i>ACS Chemical Neuroscience</i> , <b>2017</b> , 8, 2039-2055   | 5.7  | 12  |
| 80 | Genetic and Pharmacological Discovery for Alzheimer's Disease Using Caenorhabditis elegans. <i>ACS Chemical Neuroscience</i> , <b>2017</b> , 8, 2596-2606  | 5.7  | 35  |
| 79 | Dysregulation of the Mitochondrial Unfolded Protein Response Induces Non-Apoptotic Dopaminergic Neurodegeneration in Models of Parkinson's Disease. <i>Journal of Neuroscience</i> , <b>2017</b> , 37, 11085-11100   | 6.6  | 60  |
| 78 | NCEH-1 modulates cholesterol metabolism and protects against $\beta$ synuclein toxicity in a C. elegans model of Parkinson's disease. <i>Human Molecular Genetics</i> , <b>2017</b> , 26, 3823-3836  | 5.6  | 14  |
| 77 | Dopamine induces soluble $\beta$ synuclein oligomers and nigrostriatal degeneration. <i>Nature Neuroscience</i> , <b>2017</b> , 20, 1560-1568  | 25.5 | 125 |
| 76 | The Prevalence and Distribution of Neurodegenerative Compound-Producing Soil Streptomyces spp. <i>Scientific Reports</i> , <b>2016</b> , 6, 22566  | 4.9  | 6   |
| 75 | Chemical Compensation of Mitochondrial Phospholipid Depletion in Yeast and Animal Models of Parkinson's Disease. <i>PLoS ONE</i> , <b>2016</b> , 11, e0164465  | 3.7  | 7   |
| 74 | Use of Caenorhabditis elegans to Model Human Movement Disorders <b>2015</b> , 97-116   |      |     |
| 73 | A bacterial metabolite induces glutathione-tractable proteostatic damage, proteasomal disturbances, and PINK1-dependent autophagy in C. elegans. <i>Cell Death and Disease</i> , <b>2015</b> , 6, e1908  | 9.8  | 28  |
| 72 | Phenazine derivatives cause proteotoxicity and stress in C. elegans. <i>Neuroscience Letters</i> , <b>2015</b> , 584, 23-33  | 7.3  | 17  |
| 71 | Cloiquinol promotes the degradation of metal-dependent amyloid- $\beta$ oligomers to restore endocytosis and ameliorate A $\beta$ toxicity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2014</b> , 111, 4013-8 | 11.5 | 124 |
| 70 | Potentiated Hsp104 variants antagonize diverse proteotoxic misfolding events. <i>Cell</i> , <b>2014</b> , 156, 170-82  | 56.2 | 161 |
| 69 | Calcineurin determines toxic versus beneficial responses to $\beta$ synuclein. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2014</b> , 111, E3544-52  | 11.5 | 76  |
| 68 | Protective role of DNJ-27/ERdj5 in Caenorhabditis elegans models of human neurodegenerative diseases. <i>Antioxidants and Redox Signaling</i> , <b>2014</b> , 20, 217-35   | 8.4  | 40  |
| 67 | Phosphatidylethanolamine deficiency disrupts $\beta$ synuclein homeostasis in yeast and worm models of Parkinson disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2014</b> , 111, E3976-85                 | 11.5 | 48  |
| 66 | The effects of pdr1, djr1.1 and pink1 loss in manganese-induced toxicity and the role of $\beta$ synuclein in C. elegans. <i>Metallomics</i> , <b>2014</b> , 6, 476-90   | 4.5  | 71  |
| 65 | The glycolytic enzyme, GPI, is a functionally conserved modifier of dopaminergic neurodegeneration in Parkinson's models. <i>Cell Metabolism</i> , <b>2014</b> , 20, 145-57  | 24.6 | 56  |

|    |  |      |     |
|----|--|------|-----|
| 64 | Mitochondrial dysfunction, oxidative stress, and neurodegeneration elicited by a bacterial metabolite in a <i>C. elegans</i> Parkinson's model. <i>Cell Death and Disease</i> , <b>2014</b> , 5, e984                | 9.8  | 73  |
| 63 | RTCB-1 mediates neuroprotection via XBP-1 mRNA splicing in the unfolded protein response pathway. <i>Journal of Neuroscience</i> , <b>2014</b> , 34, 16076-85  | 6.6  | 30  |
| 62 | TorsinA rescues ER-associated stress and locomotive defects in <i>C. elegans</i> models of ALS. <i>DMM Disease Models and Mechanisms</i> , <b>2014</b> , 7, 233-43   | 4.1  | 21  |
| 61 | TorsinA rescues ER-associated stress and locomotive defects in <i>C. elegans</i> models of ALS. <i>Journal of Cell Science</i> , <b>2014</b> , 127, e1-e1  | 5.3  |     |
| 60 | Yeast reveal a "druggable" Rsp5/Nedd4 network that ameliorates $\beta$ synuclein toxicity in neurons. <i>Science</i> , <b>2013</b> , 342, 979-83   | 33.3 | 188 |
| 59 | Valproic acid ameliorates <i>C. elegans</i> dopaminergic neurodegeneration with implications for ERK-MAPK signaling. <i>Neuroscience Letters</i> , <b>2013</b> , 541, 116-9  | 3.3  | 17  |
| 58 | Invertebrate Models of Dystonia. <i>Current Neuropharmacology</i> , <b>2013</b> , 11, 16-29  | 7.6  | 4   |
| 57 | Lysosomal impairment in Parkinson's disease. <i>Movement Disorders</i> , <b>2013</b> , 28, 725-32  | 7    | 228 |
| 56 | Invertebrate models of dystonia. <i>Current Neuropharmacology</i> , <b>2013</b> , 11, 16-29  | 7.6  | 2   |
| 55 | Identification of novel ATP13A2 interactors and their role in $\beta$ synuclein misfolding and toxicity. <i>Human Molecular Genetics</i> , <b>2012</b> , 21, 3785-94   | 5.6  | 59  |
| 54 | A predictable worm: application of <i>Caenorhabditis elegans</i> for mechanistic investigation of movement disorders. <i>Neurotherapeutics</i> , <b>2012</b> , 9, 393-404  | 6.4  | 32  |
| 53 | The early-onset torsion dystonia-associated protein, torsinA, is a homeostatic regulator of endoplasmic reticulum stress response. <i>Human Molecular Genetics</i> , <b>2012</b> , 21, 1201-1201                     | 5.6  | 78  |
| 52 | Different 8-hydroxyquinolines protect models of TDP-43 protein, $\beta$ synuclein, and polyglutamine proteotoxicity through distinct mechanisms. <i>Journal of Biological Chemistry</i> , <b>2012</b> , 287, 4107-20 | 5.4  | 63  |
| 51 | Functional analysis of VPS41-mediated neuroprotection in <i>Caenorhabditis elegans</i> and mammalian models of Parkinson's disease. <i>Journal of Neuroscience</i> , <b>2012</b> , 32, 2142-53                       | 6.6  | 53  |
| 50 | Structural features and chaperone activity of the NudC protein family. <i>Journal of Molecular Biology</i> , <b>2011</b> , 409, 722-41   | 6.5  | 25  |
| 49 | Functional links between A $\beta$ toxicity, endocytic trafficking, and Alzheimer's disease risk factors in yeast. <i>Science</i> , <b>2011</b> , 334, 1241-5  | 33.3 | 279 |
| 48 | <i>Caenorhabditis elegans</i> as a model system for identifying effectors of $\beta$ synuclein misfolding and dopaminergic cell death associated with Parkinson's disease. <i>Methods</i> , <b>2011</b> , 53, 220-5  | 4.6  | 24  |
| 47 | TorsinA participates in endoplasmic reticulum-associated degradation. <i>Nature Communications</i> , <b>2011</b> , 2, 393  | 17.4 | 79  |

|    |   |      |     |
|----|---|------|-----|
| 46 | Inhibitors of LRRK2 kinase attenuate neurodegeneration and Parkinson-like phenotypes in <i>Caenorhabditis elegans</i> and <i>Drosophila</i> Parkinson's disease models. <i>Human Molecular Genetics</i> , <b>2011</b> , 20, 3933-42 | 5.6  | 107 |
| 45 | Modeling dopamine neuron degeneration in <i>Caenorhabditis elegans</i> . <i>Methods in Molecular Biology</i> , <b>2011</b> , 793, 129-48  | 1.4  | 24  |
| 44 | Cell Culture to Investigate Neurotoxicity and Neurodegeneration Utilizing <i>Caenorhabditis elegans</i> . <i>Neuromethods</i> , <b>2011</b> , 129-143   | 0.4  |     |
| 43 | Methodological Strategies to Evaluate Functional Effectors Related to Parkinson's Disease Through Application of <i>Caenorhabditis elegans</i> Models. <i>Neuromethods</i> , <b>2011</b> , 31-53                                    | 0.4  |     |
| 42 | Low-dose bafilomycin attenuates neuronal cell death associated with autophagy-lysosome pathway dysfunction. <i>Journal of Neurochemistry</i> , <b>2010</b> , 114, 1193-204  | 6    | 50  |
| 41 | The early-onset torsion dystonia-associated protein, torsinA, is a homeostatic regulator of endoplasmic reticulum stress response. <i>Human Molecular Genetics</i> , <b>2010</b> , 19, 3502-15                                      | 5.6  | 79  |
| 40 | Differential neuroprotective effects of 14-3-3 proteins in models of Parkinson's disease. <i>Cell Death and Disease</i> , <b>2010</b> , 1, e2   | 9.8  | 89  |
| 39 | Chemical enhancement of torsinA function in cell and animal models of torsion dystonia. <i>DMM Disease Models and Mechanisms</i> , <b>2010</b> , 3, 386-96  | 4.1  | 47  |
| 38 | Disinfecting dystonia? Drug discovery using worms identifies an antibiotic as a neuroprotective lead molecule for movement disorders. <i>Future Neurology</i> , <b>2010</b> , 5, 473-476  | 1.5  |     |
| 37 | Compounds from an unbiased chemical screen reverse both ER-to-Golgi trafficking defects and mitochondrial dysfunction in Parkinson's disease models. <i>DMM Disease Models and Mechanisms</i> , <b>2010</b> , 3, 194-208            | 4.1  | 147 |
| 36 | The early-onset torsion dystonia-associated protein, torsinA, displays molecular chaperone activity in vitro. <i>Cell Stress and Chaperones</i> , <b>2010</b> , 15, 605-17  | 4    | 46  |
| 35 | VPS41, a protein involved in lysosomal trafficking, is protective in <i>Caenorhabditis elegans</i> and mammalian cellular models of Parkinson's disease. <i>Neurobiology of Disease</i> , <b>2010</b> , 37, 330-8                   | 7.5  | 64  |
| 34 | <i>C. elegans</i> as a model organism to investigate molecular pathways involved with Parkinson's disease. <i>Developmental Dynamics</i> , <b>2010</b> , 239, 1282-95   | 2.9  | 91  |
| 33 | Investigating bacterial sources of toxicity as an environmental contributor to dopaminergic neurodegeneration. <i>PLoS ONE</i> , <b>2009</b> , 4, e7227   | 3.7  | 39  |
| 32 | Pharmacogenetic analysis reveals a post-developmental role for Rac GTPases in <i>Caenorhabditis elegans</i> GABAergic neurotransmission. <i>Genetics</i> , <b>2009</b> , 183, 1357-72   | 4    | 17  |
| 31 | The microtubule-associated protein, NUD-1, exhibits chaperone activity in vitro. <i>Cell Stress and Chaperones</i> , <b>2009</b> , 14, 95-103   | 4    | 20  |
| 30 | Rapid selection of cyclic peptides that reduce alpha-synuclein toxicity in yeast and animal models. <i>Nature Chemical Biology</i> , <b>2009</b> , 5, 655-63  | 11.7 | 117 |
| 29 | Alpha-synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity. <i>Nature Genetics</i> , <b>2009</b> , 41, 308-15   | 36.3 | 451 |

|    |   |      |      |
|----|---|------|------|
| 28 | The Nematode, <i>Caenorhabditis elegans</i> , as an Emerging Model for Investigating Epilepsy. <i>Neuromethods</i> , <b>2009</b> , 1-25   | 0.4  | 1    |
| 27 | Investigating Molecular Chaperone Activity Associated with Human TorsinA. <i>FASEB Journal</i> , <b>2009</b> , 23, 673.1  | 0.9  |      |
| 26 | Lysosomal enzyme cathepsin D protects against alpha-synuclein aggregation and toxicity. <i>Molecular Brain</i> , <b>2008</b> , 1, 17  | 4.5  | 191  |
| 25 | Acetaminophen attenuates dopamine neuron degeneration in animal models of Parkinson's disease. <i>Neuroscience Letters</i> , <b>2008</b> , 439, 129-33  | 3.3  | 66   |
| 24 | Animal models for drug discovery in dystonia. <i>Expert Opinion on Drug Discovery</i> , <b>2008</b> , 3, 83-97  | 6.2  | 20   |
| 23 | The Parkinson's disease protein alpha-synuclein disrupts cellular Rab homeostasis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2008</b> , 105, 145-50               | 11.5 | 415  |
| 22 | Hypothesis-based RNAi screening identifies neuroprotective genes in a Parkinson's disease model. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2008</b> , 105, 728-33 | 11.5 | 238  |
| 21 | Traversing a wormhole to combat Parkinson's disease. <i>DMM Disease Models and Mechanisms</i> , <b>2008</b> , 1, 32-6   | 4.1  | 12   |
| 20 | Application of a <i>C. elegans</i> dopamine neuron degeneration assay for the validation of potential Parkinson's disease genes. <i>Journal of Visualized Experiments</i> , <b>2008</b> ,                           | 1.6  | 24   |
| 19 | Paradigms for pharmacological characterization of <i>C. elegans</i> synaptic transmission mutants. <i>Journal of Visualized Experiments</i> , <b>2008</b> ,   | 1.6  | 12   |
| 18 | Generation of stable transgenic <i>C. elegans</i> using microinjection. <i>Journal of Visualized Experiments</i> , <b>2008</b> ,  | 1.6  | 58   |
| 17 | Ubiquitin conjugating enzymes participate in polyglutamine protein aggregation. <i>BMC Cell Biology</i> , <b>2007</b> , 8, 32   |      | 14   |
| 16 | Genetic interactions among cortical malformation genes that influence susceptibility to convulsions in <i>C. elegans</i> . <i>Brain Research</i> , <b>2006</b> , 1120, 23-34  | 3.7  | 35   |
| 15 | Deletion of the ubiquitin ligase CHIP leads to the accumulation, but not the aggregation, of both endogenous phospho- and caspase-3-cleaved tau species. <i>Journal of Neuroscience</i> , <b>2006</b> , 26, 6985-96 | 6.6  | 202  |
| 14 | Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. <i>Science</i> , <b>2006</b> , 313, 324-8   | 33.3 | 1084 |
| 13 | Torsin-mediated protection from cellular stress in the dopaminergic neurons of <i>Caenorhabditis elegans</i> . <i>Journal of Neuroscience</i> , <b>2005</b> , 25, 3801-12   | 6.6  | 229  |
| 12 | Use of <i>C. elegans</i> to Model Human Movement Disorders <b>2005</b> , 111-126  |      | 1    |
| 11 | Epileptic-like convulsions associated with LIS-1 in the cytoskeletal control of neurotransmitter signaling in <i>Caenorhabditis elegans</i> . <i>Human Molecular Genetics</i> , <b>2004</b> , 13, 2043-59           | 5.6  | 65   |

|    |   |     |     |
|----|---|-----|-----|
| 10 | Using <i>Caenorhabditis elegans</i> to probe toxicity of 1-alkyl-3-methylimidazolium chloride based ionic liquids. <i>Chemical Communications</i> , <b>2004</b> , 668-9                         | 5.8 | 165 |
| 9  | An animal model to discern torsin function: suppression of protein aggregation in <i>C. elegans</i> . <i>Advances in Neurology</i> , <b>2004</b> , 94, 79-85                                    |     | 7   |
| 8  | Role for NudC, a dynein-associated nuclear movement protein, in mitosis and cytokinesis. <i>Journal of Cell Science</i> , <b>2003</b> , 116, 1991-2003  | 5.3 | 92  |
| 7  | Suppression of polyglutamine-induced protein aggregation in <i>Caenorhabditis elegans</i> by torsin proteins. <i>Human Molecular Genetics</i> , <b>2003</b> , 12, 307-19                        | 5.6 | 115 |
| 6  | Evolutionarily conserved nuclear migration genes required for early embryonic development in <i>Caenorhabditis elegans</i> . <i>Development Genes and Evolution</i> , <b>2001</b> , 211, 434-41 | 1.8 | 45  |
| 5  | arrow encodes an LDL-receptor-related protein essential for Wingless signalling. <i>Nature</i> , <b>2000</b> , 407, 527-30  | 5.4 | 712 |
| 4  | A genetic strategy for differential screening of meiotic germ-cell cDNA libraries. <i>Molecular Reproduction and Development</i> , <b>1996</b> , 43, 403-13                                     | 2.6 | 6   |
| 3  | Induced premature G2/M-phase transition in pachytene spermatocytes includes events unique to meiosis. <i>Developmental Biology</i> , <b>1995</b> , 169, 557-67                                  | 3.1 | 112 |
| 2  | Therapeutic genetic variation revealed in diverse Hsp104 homologs   |     | 1   |
| 1  | Tuning Hsp104 specificity to selectively detoxify $\beta$ synuclein   |     | 3   |